Promedior is currently conducting two Phase 2 clinical trials of its product candidate, PRM-151, in patients with Myelofibrosis (MF) and Idiopathic Pulmonary Fibrosis (IPF). PRM-151 is formulated for intravenous injection. Both of these studies have completed enrollment and are no longer recruiting patients.
PRM-151G-101: A Phase 2, Prospective Study of PRM-151 in Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), Or Post-Essential Thrombocythemia MF (post-ET MF)
PRM-151-202: A Phase 2 Trial to Evaluate the Efficacy of PRM-151 in Subjects with Idiopathic Pulmonary Fibrosis (IPF)